Htr1D Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
| Attribute | Value | |-----------|-------| | Protein Name | 5-HT1D Receptor | | Gene Symbol | HTR1D | | UniProt ID | [P28221](https://www.uniprot.org/uniprot/P28221) | | Molecular Weight | ~41 kDa | | Subcellular Localization | Plasma membrane | | Protein Family | 5-HT1 receptor family | | Structure | 7-transmembrane GPCR |
</div>}
Overview
The 5-HT1D receptor (HTR1D) is a G protein-coupled receptor (GPCR) that binds serotonin (5-hydroxytryptamine) with high affinity and mediates inhibitory neurotransmission in the central and peripheral nervous systems[@hoyer1994]. This receptor belongs to the 5-HT1 family, which includes 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F subtypes. HTR1D is characterized by its Gi/o protein coupling, which inhibits adenylate cyclase and reduces intracellular cAMP levels[@barnes1999]. The receptor is predominantly expressed in the trigeminal ganglion, cranial vasculature, and specific brain regions, making it a crucial target for migraine therapy and neurological research.
Structure
The 5-HT1D receptor possesses the classic seven-transmembrane domain structure characteristic of class A GPCRs[@saxena1995]:
...
5-HT1D Receptor Protein
Introduction
Htr1D Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
| Attribute | Value | |-----------|-------| | Protein Name | 5-HT1D Receptor | | Gene Symbol | HTR1D | | UniProt ID | [P28221](https://www.uniprot.org/uniprot/P28221) | | Molecular Weight | ~41 kDa | | Subcellular Localization | Plasma membrane | | Protein Family | 5-HT1 receptor family | | Structure | 7-transmembrane GPCR |
</div>}
Overview
The 5-HT1D receptor (HTR1D) is a G protein-coupled receptor (GPCR) that binds serotonin (5-hydroxytryptamine) with high affinity and mediates inhibitory neurotransmission in the central and peripheral nervous systems[@hoyer1994]. This receptor belongs to the 5-HT1 family, which includes 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F subtypes. HTR1D is characterized by its Gi/o protein coupling, which inhibits adenylate cyclase and reduces intracellular cAMP levels[@barnes1999]. The receptor is predominantly expressed in the trigeminal ganglion, cranial vasculature, and specific brain regions, making it a crucial target for migraine therapy and neurological research.
Structure
The 5-HT1D receptor possesses the classic seven-transmembrane domain structure characteristic of class A GPCRs[@saxena1995]:
Transmembrane Domains
Seven hydrophobic alpha-helices (TM1-TM7) spanning the plasma membrane
Connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3)
Highly conserved sequences in TM6 and TM7 for ligand binding
Key Structural Features
DRY motif (Arg-Asp-Tyr) in intracellular loop 3 for G protein coupling
NPxxY motif in TM7 for receptor activation and desensitization
Cysteine residues in extracellular loops forming disulfide bonds
N-linked glycosylation sites in the N-terminus and extracellular loops
Palmitoylation sites in the C-terminus for membrane anchoring
Ligand Binding
The ligand-binding pocket is formed by residues in:
Transmembrane domains 3, 5, 6, and 7
Extracellular loop 2
Key binding site residues include Asp^3.32, Ser^5.43, and Thr^6.55
Normal Function
HTR1D mediates multiple physiological processes through Gi/o protein signaling[@middlemiss1990]:
Neurotransmission
Presynaptic autoreceptor: Located on serotonergic nerve terminals to inhibit further serotonin release
Postsynaptic receptor: Modulates neuronal excitability in target regions
Biomarkers: HTR1D as predictor of treatment response
Background
The study of Htr1D Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Hoyer D, Clarke DE, Fozard JR, et al, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) (1994)](https://pubmed.ncbi.nlm.nih.gov/7938165/)
[Barnes NM, Sharp T, A review of central 5-HT receptors and their function (1999)](https://pubmed.ncbi.nlm.nih.gov/10457221/)
Saxena A, Villalon CM, 5-HT1D receptors: effect of selective ligands and therapeutic potential (1995)
[Middlemiss DN, Hutson PH, The 5-HT1B receptors (1990)](https://pubmed.ncbi.nlm.nih.gov/2252301/)
[Humphrey PP, Feniuk W, Mode of action of the anti-migraine drug sumatriptan (GR43175) (1991)](https://pubmed.ncbi.nlm.nih.gov/1790798/)
[Hoyer D, Martin G, 5-HT receptor classification and nomenclature: towards a harmonization with the human genome (1997)](https://pubmed.ncbi.nlm.nih.gov/9176810/)